Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9129MR)

This product GTTS-WQ9129MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9129MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7287MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ13372MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ4975MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ12292MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ5459MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ2512MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ12260MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW